Related Experiment Video

Updated: Aug 16, 2026

The Adjuvant Efficacy of Angong Niuhuang Pill in the Treatment of Viral Encephalitis: A Meta-Analysis of Randomized Controlled Trials
08:36

The Adjuvant Efficacy of Angong Niuhuang Pill in the Treatment of Viral Encephalitis: A Meta-Analysis of Randomized Controlled Trials

Published on: April 19, 2024

AIDS-associated progressive multifocal leukoencephalopathy : current management strategies

Mark T M Roberts1

  • 1Department of Infectious Diseases, Addenbrooke's Hospital, Cambridge, UK. mtmr1@cam.ac.uk

CNS Drugs
|August 16, 2005
PubMed

Insights

Progressive multifocal leukoencephalopathy (PML), a JC virus infection, causes severe neurological deficits in immunocompromised individuals. While HAART has improved outcomes, new JCV-specific therapies and diagnostics are crucial for better treatment and understanding.

Area of Science:

  • Neurovirology
  • Immunology
  • Infectious Diseases

Background:

  • Progressive multifocal leukoencephalopathy (PML) is a rare, opportunistic central nervous system (CNS) infection caused by the JC virus (JCV).
  • PML occurs in patients with severe, prolonged immunosuppression, a condition increasingly prevalent since the AIDS pandemic.
  • The disease involves oligodendrocyte lysis and demyelination, leading to rapid neurological decline and high mortality without treatment.

Purpose of the Study:

  • To review the current understanding of PML, its pathogenesis, and treatment landscape.
  • To highlight the impact of highly active antiretroviral therapy (HAART) on PML prognosis.
  • To discuss emerging diagnostic tools and novel therapeutic strategies for JCV infections.

Main Methods:

  • Literature review of PML, JC virus, and associated immunosuppressive conditions.
  • Analysis of treatment outcomes before and after the introduction of HAART.
  • Examination of current research into novel anti-JCV agents, immunotherapy, and gene therapy.

Main Results:

  • PML is characterized by demyelination and rapid neurological deficits, with a median survival of 3.5 months pre-HAART.
  • HAART has significantly improved PML prognosis, but some patients remain unresponsive or develop immune reconstitution disease.
  • Advancements in understanding JCV biology are paving the way for new, targeted therapies.

Conclusions:

  • Despite improved outcomes with HAART, PML remains a significant challenge in immunocompromised patients.
  • Further research into JCV-specific agents, improved diagnostics, immunotherapy, and gene therapy is essential.
  • A comprehensive understanding of JCV-host interactions is key to developing more effective treatments for PML.

More Related Videos

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis06:19

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

Related Concept Videos

Cryptococcal Meningitis01:27

Cryptococcal Meningitis

Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Pharmaceutical Poisoning: Treatment Strategies01:26

Pharmaceutical Poisoning: Treatment Strategies

Treatment strategies for poisoning are a critical aspect of emergency medicine, focusing on preventing the absorption of toxins and enhancing their elimination. When a poisoning incident occurs, the first response is to halt exposure and decontaminate the patient, particularly through gastrointestinal (GI) methods if the poison was ingested.Gastrointestinal Decontamination Techniques:Activated charcoal is the cornerstone of GI decontamination. It works through adsorption, binding the toxin to...
Antiprotozoal Agents01:21

Antiprotozoal Agents

Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...
Encephalitis ll: Pathophysiology01:26

Encephalitis ll: Pathophysiology

Encephalitis is inflammation of the brain parenchyma caused by direct viral invasion or immune-mediated mechanisms triggered by infections or tumors. Both processes lead to neuronal injury, disrupted neurotransmission, and diverse neurological symptoms, often with overlapping clinical and pathological features.Autoimmune EncephalitisIn autoimmune encephalitis, antibodies target neuronal antigens on cell surfaces, synapses, or within neurons. A key example is anti-NMDAR encephalitis, which can...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...